Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Ann Pharmacother. 2011 May;45(5):e24. doi: 10.1345/aph.1P586. Epub 2011 Apr 26.
To report a case of refractory atypical Alternaria keratitis that was treated with intrastromal and topical caspofungin 0.5% in combination with topical, oral, and intrastromal voriconazole.
A 67-year-old female with a history of bilateral intraocular lens exchange and left pseudophakic bullous keratopathy was referred to the emergency department of the Royal Victorian Eye and Ear Hospital, Melbourne, Australia. Visual acuity of her left eye was limited to counting fingers. A fine branching pattern was noted throughout the anterior stroma of her left corneal graft. The anterior chamber was deep and quiet. Hourly topical voriconazole 1% was initiated, with limited response. One week later, Alternaria spp. was cultured from the corneal scraping. Subsequently, topical caspofungin 0.5% was added, with concomitant use of topical, oral, and intrastromal voriconazole. Despite gradual symptomatic improvement, topical voriconazole was increased to 2% and intrastromal caspofungin was added. The patient was discharged after almost 5 weeks of treatment. Topical voriconazole 2% and topical caspofungin 0.5% were continued for an additional 3 weeks and 1 week, respectively, in the outpatient setting. The patient underwent left penetrating keratoplasty 3 weeks postdischarge. Visual acuity was stable at 20/150, with no reported adverse event 15 months postoperative.
Treatment for Alternaria keratitis remains challenging, as it is refractory to existing antifungal agents. To our knowledge, this is the first reported instance of the use of intrastromal caspofungin to treat Alternaria keratitis in a case in which clinical resolution was not fully achieved despite the use of topical caspofungin in addition to extensive use of topical, intrastromal, and oral voriconazole. This case highlights the importance of intensive pharmacologic management and therapeutic penetrating keratoplasty in preventing evisceration of the patient's eye, especially when Alternaria keratitis is involved.
Intrastromal and topical caspofungin were employed in combination with voriconazole for the management of refractory Alternaria keratitis, with no observed adverse effects.
报告一例难治性非典型交链孢菌角膜炎,该患者接受了基质内和局部注射 0.5%两性霉素 B 联合局部、口服和基质内伏立康唑治疗。
一位 67 岁女性,有双侧人工晶状体置换和左眼假性囊膜性角膜病变史,转诊至澳大利亚墨尔本皇家维多利亚眼耳医院急诊部。她左眼视力仅能数指。左眼角膜移植片的前基质中可见细分支模式。前房深且安静。开始每小时局部滴注 1%伏立康唑,效果有限。一周后,从角膜刮片中培养出链格孢菌属。随后,加用局部两性霉素 B 0.5%,同时使用局部、口服和基质内伏立康唑。尽管症状逐渐改善,但仍将局部伏立康唑增加至 2%,并加用基质内两性霉素 B。患者经过近 5 周的治疗后出院。在门诊继续使用局部伏立康唑 2%和局部两性霉素 B 0.5%治疗 3 周和 1 周。出院后 3 周,患者行左眼穿透性角膜移植术。术后 15 个月,视力稳定在 20/150,无不良事件报告。
交链孢菌角膜炎的治疗仍然具有挑战性,因为它对现有的抗真菌药物有抗药性。据我们所知,这是首例报道的使用基质内两性霉素 B 治疗交链孢菌角膜炎的病例,尽管联合使用了局部两性霉素 B,并广泛使用了局部、基质内和口服伏立康唑,但临床缓解并未完全达到。该病例强调了在预防患者眼球内容物脱出方面,强化药物治疗和穿透性角膜移植术的重要性,尤其是在涉及交链孢菌角膜炎时。
联合使用伏立康唑治疗难治性交链孢菌角膜炎时,采用了基质内和局部两性霉素 B,未观察到不良反应。